Trial site
University of Kentucky Chandler Medical Center
Lexington, Kentucky 40536, United StatesNot linked to an institution yet
- 16running trials
- 3closed trials
The trials here
What the 20 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 25 trials
- Phase 2/32 trials
- Phase 11 trial
- Phase 1/21 trial
- Status
- Recruiting9 trials
- Active, not recruiting6 trials
- Terminated2 trials
- Completed1 trial
- Not yet recruiting1 trial
- Suspended1 trial
- Lead sponsor
- Eli Lilly and Company6 trials
- Bristol-Myers Squibb3 trials
- Francis Farhadi2 trials
- Bausch Health Americas, Inc.1 trial
- BioNTech SE1 trial
- and 7 more
Running trials
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497· Phase 3· Bristol-Myers Squibb· Source
Contact: Zhonglin Hao, Site 0656
Recruiting
A Study of Brenipatide in Participants With Opioid Use Disorder
NCT07420283· Phase 2· Eli Lilly and Company· Source
Contact: Shanna Babalonis (principal investigator)
Recruiting
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
NCT07428538· Phase 3· Bausch Health Americas, Inc.· Source
Contact: Varsha Bhatt, PhD
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source
Contact: John Villano, Site 0125
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· Phase 3· Eli Lilly and Company· Source
Contact: Rachel Miller (principal investigator)
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Zin Myint, Site 0193
Recruiting
Evaluating Safety and Feasibility of Transcutaneous Spinal Cord Stimulation Following Traumatic and Non-Traumatic Spinal Cord Injury: A Pilot Study
NCT06520020· Francis Farhadi· Source
Contact: Francis H Farhadi, MD, PhD
Active, not recruiting
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
NCT06384261· Phase 2· OncoVerity, Inc.· Source
Recruiting
Spinal Decompression Plus Nerve Graft Implantation Following TSCI
NCT06243211· Francis Farhadi· Source
Contact: Francis Farhadi, MD, PhD
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· Phase 3· Eli Lilly and Company· Source
Contact: Susanne Arnold (principal investigator)
Active, not recruiting
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095· Phase 3· Janssen-Cilag Ltd.· Source
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
NCT05142189· Phase 1· BioNTech SE· Source
Active, not recruiting
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
NCT04647526· Phase 3· POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company· Source
Active, not recruiting
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
NCT04616326· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
NCT03432286· Phase 3· Eli Lilly and Company· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error